DrugPatentWatch Database Preview
EPZICOM Drug Profile
Which patents cover Epzicom, and what generic alternatives are available?
Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Summary for EPZICOM
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 54 |
| Clinical Trials: | 21 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EPZICOM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EPZICOM |
| DailyMed Link: | EPZICOM at DailyMed |
Pharmacology for EPZICOM
Synonyms for EPZICOM
| (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| (+/-)-Abacavir |
| (+/-)-cis-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| [(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9-purinyl]-1-cyclopent-2-enyl]methanol |
| [(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol |
| [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol |
| [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol |
| [(1S,4R)-4-[2-azanyl-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol |
| {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol |
| {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol |
| 136470-78-5 |
| 136470-78-5 (Succinate) |
| 1592U89 |
| 188062-50-2 |
| 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)- |
| 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)- |
| 470A785 |
| A807079 |
| AB01566826_01 |
| abacavir |
| Abacavir (INN) |
| Abacavir [INN:BAN] |
| Abacavir [INN] |
| Abacavir sulfate |
| AC-1299 |
| AC1L9AXG |
| ACT03218 |
| AK163479 |
| AKOS024464970 |
| AM015240 |
| BC214924 |
| BDBM50366816 |
| Bio-0001 |
| C-18039 |
| C07624 |
| CC-23613 |
| CHEBI:421707 |
| CHEMBL1380 |
| CJ-31308 |
| CS-1354 |
| D07057 |
| D0A4IJ |
| DB01048 |
| DR001043 |
| EN300-258000 |
| Epitope ID:137341 |
| FT-0631153 |
| HE058172 |
| HY-17423 |
| J-700136 |
| KS-00000XJM |
| MCGSCOLBFJQGHM-SCZZXKLOSA-N |
| MFCD00903850 |
| MLS006010117 |
| MolPort-006-069-118 |
| NCGC00164560-01 |
| NCGC00164560-02 |
| NSC742406 |
| NU000340 |
| SC-16996 |
| SC-20023 |
| SCHEMBL38632 |
| SMR004701251 |
| ST24045890 |
| UNII-WR2TIP26VS |
| W-5205 |
| WR2TIP26VS |
| Ziagen |
| Ziagen (TM)(*Succinate salt*) |
| Ziagen (TN) |
| ZINC2015928 |
US Patents and Regulatory Information for EPZICOM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for EPZICOM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | ➤ Sign Up | ➤ Sign Up |
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | ➤ Sign Up | ➤ Sign Up |
| Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for EPZICOM
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for EPZICOM
Supplementary Protection Certificates for EPZICOM
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0022 | France | ➤ Sign Up | PRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217 |
| 99C0033 | Belgium | ➤ Sign Up | PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628 |
| 0817637/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
